Genix Pharmaceuticals Corporation (GENPF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GENPF steht fuer Genix Pharmaceuticals Corporation, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 38/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 15. März 2026Genix Pharmaceuticals Corporation (GENPF) Gesundheitswesen & Pipeline-Uebersicht
Genix Pharmaceuticals Corporation is a Canadian life sciences company focused on developing, manufacturing, and marketing nutraceuticals and pharmaceuticals. Their product portfolio includes antiviral treatments like Flu-X, dietary supplements such as Renochlor, and a variety of nutraceutical products, positioning them in the specialty and generic drug market.
Investmentthese
Genix Pharmaceuticals Corporation presents a speculative investment opportunity within the specialty and generic drug market. The company's focus on nutraceuticals and pharmaceuticals, including novel products like Flu-X and Renochlor, could drive revenue growth if these products gain market acceptance. However, the company's small market capitalization and OTC listing introduce significant risks. Key value drivers include successful product commercialization, expansion of distribution networks, and potential partnerships. The negative P/E ratio of -3.80 indicates the company is currently not profitable, requiring careful monitoring of financial performance. The beta of 0.49 suggests lower volatility compared to the overall market. Investors should assess the company's ability to execute its growth strategy and navigate the competitive landscape.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Focus on nutraceuticals and pharmaceuticals, targeting a growing market segment.
- Development of Flu-X, an antiviral product, addressing the demand for cold and flu remedies.
- Renochlor, a dietary supplement, caters to the increasing awareness of kidney health.
- Sucanon, an insulin sensitizer, aims to address the needs of individuals managing blood sugar levels.
- OTC listing provides access to capital but also introduces higher risks and regulatory scrutiny.
Wettbewerber & Vergleichsunternehmen
Staerken
- Diverse product portfolio in nutraceuticals and pharmaceuticals.
- Development of innovative products like Flu-X and Renochlor.
- Established manufacturing capabilities.
- Presence in the Canadian market.
Schwaechen
- Small market capitalization.
- OTC listing increases risk and regulatory scrutiny.
- Negative P/E ratio indicates lack of profitability.
- Limited geographic reach.
Katalysatoren
- Upcoming: Potential regulatory approvals for new pharmaceutical products.
- Ongoing: Expansion of distribution networks and strategic partnerships.
- Ongoing: Increasing demand for nutraceuticals and dietary supplements.
- Upcoming: Positive clinical trial results for key products.
- Ongoing: Growth in online sales and marketing efforts.
Risiken
- Potential: Intense competition from established pharmaceutical companies.
- Potential: Evolving regulatory landscape and compliance requirements.
- Ongoing: Limited financial resources and profitability.
- Potential: Product liability claims and recalls.
- Ongoing: Economic downturn affecting consumer spending.
Wachstumschancen
- Expansion of Product Portfolio: Genix Pharmaceuticals can expand its product portfolio by developing and launching new nutraceutical and pharmaceutical products. The global nutraceuticals market is projected to reach $500 billion by 2025, providing ample opportunities for growth. Timeline: Ongoing.
- Geographic Expansion: Genix Pharmaceuticals can expand its geographic reach beyond Canada by entering new markets in North America, Europe, and Asia. The increasing demand for nutraceuticals and generic drugs in these regions presents significant growth opportunities. Timeline: 2-3 years.
- Strategic Partnerships: Genix Pharmaceuticals can form strategic partnerships with distributors, retailers, and other healthcare providers to expand its distribution network and reach a wider customer base. Collaborations can also facilitate product development and marketing efforts. Timeline: Ongoing.
- Online Sales and Marketing: Genix Pharmaceuticals can invest in online sales and marketing channels to reach a broader audience and increase brand awareness. E-commerce platforms and digital marketing campaigns can drive sales and reduce reliance on traditional distribution channels. Timeline: 1 year.
- Research and Development: Genix Pharmaceuticals can invest in research and development to develop innovative products and gain a competitive edge. Focusing on novel formulations and delivery systems can differentiate the company from its competitors. Timeline: Ongoing.
Chancen
- Expansion into new geographic markets.
- Strategic partnerships with distributors and retailers.
- Development of new and innovative products.
- Increased online sales and marketing efforts.
Risiken
- Intense competition from established pharmaceutical companies.
- Evolving regulatory landscape.
- Potential product liability claims.
- Economic downturn affecting consumer spending.
Wettbewerbsvorteile
- Proprietary formulations for certain products.
- Established manufacturing capabilities.
- Brand recognition in the Canadian market.
Ueber GENPF
Genix Pharmaceuticals Corporation, formerly known as Alta Natural Herbs & Supplements Ltd., was incorporated in 1993 and rebranded in June 2019 to reflect its expanded focus on pharmaceuticals. Based in Vancouver, Canada, the company formulates, manufactures, licenses, and markets life sciences related products. Genix Pharmaceuticals operates primarily in the nutraceutical and pharmaceutical sectors, developing products aimed at addressing various health needs. Their key products include Flu-X, an herbal antiviral product targeting flu and common cold coronaviruses, available in oral and spray forms; Renochlor, a dietary supplement designed to support kidney health and function; and Sucanon, an insulin sensitizer intended to lower blood sugar levels. Additionally, Genix Pharmaceuticals markets a range of nutraceuticals, including bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder. The company also offers eye ointments and drops, further diversifying its product offerings within the healthcare market. Genix Pharmaceuticals aims to provide accessible and effective healthcare solutions through its diverse product line.
Was das Unternehmen tut
- Formulates and manufactures nutraceuticals and pharmaceuticals.
- Licenses and markets life sciences related products.
- Develops antiviral products like Flu-X.
- Offers dietary supplements such as Renochlor.
- Markets insulin sensitizers like Sucanon.
- Sells a range of nutraceutical products, including bee propolis capsules and fish oil softgels.
- Provides eye ointments and drops.
Geschaeftsmodell
- Develops and manufactures nutraceutical and pharmaceutical products.
- Markets and sells products through various distribution channels.
- Generates revenue through product sales and licensing agreements.
Branchenkontext
Genix Pharmaceuticals Corporation operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and evolving regulatory landscapes. The global nutraceuticals market is experiencing steady growth, driven by increasing consumer awareness of preventive healthcare and the rising prevalence of chronic diseases. The pharmaceutical industry is also undergoing significant changes, with a growing emphasis on generic drugs and biosimilars to reduce healthcare costs. Genix Pharmaceuticals competes with both established pharmaceutical companies and smaller nutraceutical manufacturers. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products.
Wichtige Kunden
- Individuals seeking nutraceuticals and dietary supplements.
- Patients requiring pharmaceutical treatments.
- Retailers and distributors of healthcare products.
Finanzdaten
Chart & Info
Genix Pharmaceuticals Corporation (GENPF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer GENPF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer GENPF.
Kursziele
Wall-Street-Kurszielanalyse fuer GENPF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von GENPF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Sina Salehi Pirooz
CEO
Sina Salehi Pirooz serves as the Chief Executive Officer of Genix Pharmaceuticals Corporation. His background includes experience in the pharmaceutical and nutraceutical industries, with a focus on product development and marketing. He has been involved in the development and commercialization of several key products for Genix Pharmaceuticals. His expertise lies in identifying market opportunities and driving the company's growth strategy.
Erfolgsbilanz: Under Sina Salehi Pirooz's leadership, Genix Pharmaceuticals has focused on expanding its product portfolio and entering new markets. Key achievements include the development and launch of Flu-X and Renochlor. He has also overseen the company's rebranding efforts and its transition to a more pharmaceutical-focused business model.
GENPF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it difficult for investors to assess their financial health and operational performance. These securities are often considered highly speculative due to the lack of regulatory oversight and transparency compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Established manufacturing capabilities.
- Presence in the Canadian market.
- Development of innovative products like Flu-X and Renochlor.
Haeufige Fragen zu GENPF
What are the key factors to evaluate for GENPF?
Genix Pharmaceuticals Corporation (GENPF) currently holds an AI score of 38/100, indicating low score. Key strength: Diverse product portfolio in nutraceuticals and pharmaceuticals.. Primary risk to monitor: Potential: Intense competition from established pharmaceutical companies.. This is not financial advice.
How frequently does GENPF data refresh on this page?
GENPF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GENPF's recent stock price performance?
Recent price movement in Genix Pharmaceuticals Corporation (GENPF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse product portfolio in nutraceuticals and pharmaceuticals.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GENPF overvalued or undervalued right now?
Determining whether Genix Pharmaceuticals Corporation (GENPF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GENPF?
Before investing in Genix Pharmaceuticals Corporation (GENPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GENPF to a portfolio?
Potential reasons to consider Genix Pharmaceuticals Corporation (GENPF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Diverse product portfolio in nutraceuticals and pharmaceuticals.. Additionally: Development of innovative products like Flu-X and Renochlor.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of GENPF?
Yes, most major brokerages offer fractional shares of Genix Pharmaceuticals Corporation (GENPF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track GENPF's earnings and financial reports?
Genix Pharmaceuticals Corporation (GENPF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for GENPF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available company data and may be limited due to OTC listing.
- AI analysis pending for GENPF.